ABCG2 Cancer Research Results

ABCG2, BCRP/ATP-binding cassette sub-family G member 2: Click to Expand ⟱
Source:
Type:
ATP-binding cassette sub-family G member 2 (ABCG2) is a protein that plays a crucial role in the transport of various substances across cell membranes, including drugs, lipids, and xenobiotics. ABCG2 is often high and associated with poor prognosis.

BCRP (ABCG2; breast cancer resistance protein) is an ATP-binding cassette efflux transporter that can export multiple anticancer drugs from cancer cells. In tumors, increased BCRP activity may lower intracellular drug accumulation and contribute to multidrug resistance, reduced chemotherapy response, and survival of resistant cancer stem-like or side-population cells. Therefore, for anti-cancer interpretation, BCRP/ABCG2 downregulation or inhibition is generally favorable when the therapeutic goal is to increase intracellular exposure to BCRP-substrate drugs. However, BCRP also protects normal tissues such as intestinal epithelium, liver, kidney, placenta, and blood-brain barrier, so systemic inhibition may alter drug distribution and toxicity.



Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
61- QC,    Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, ARPE-19
p‑PI3K↓, p‑Akt↓, p‑ERK↓, NF-kB↓, p38↓, ABCG2↓, CD44↓, CD133↓, CSCs↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

p‑Akt↓, 1,   p38↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD44↓, 1,   CSCs↓, 1,   p‑ERK↓, 1,   p‑PI3K↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ABCG2↓, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: ABCG2, BCRP/ATP-binding cassette sub-family G member 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:900  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page